USPTO serial 79238385
OMERO
Reviewed by CopyMark Law Group
Reg. 5802880Status 739Registered
- Filing date
- Status date
- Registration date
- Jul 16, 2019
- Examiner
- LEASER, ANDREW C
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with OMERO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stacey J. Watson, Esq.
Stacey J. Watson, Esq. MARKERY LAW LLCP.O. BOX 84150GAITHERSBURG, MD 20883-4150United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Computer software, including computer software downloadable from the Internet, for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; data access and data management software tools for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable electronic publications in the nature of scientific journals, periodicals and newsletters relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof * | ACTIVE | — |
| 035 | Business services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science, namely, management of biological and biomedical data and images for business enterprises; data processing services; all the aforesaid services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images, all being for use in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof * | ACTIVE | — |
| 042 | Design and development of computer software, software tools, data access tools and data management tools; computer programming; installation, maintenance and repair of computer software; design of computer websites and maintenance thereof; software as a service (SAAS) featuring software for the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; all the aforesaid services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images, all being for use in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof * | ACTIVE | — |
| 045 | Licensing of computer software for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images, all being for use in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; * none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof * | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glencoe Software Inc.
- Other trademarks owned by Glencoe Software Inc.
- Other trademarks owned by Glencoe Software Inc.
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named OMERO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 6, 2025 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Nov 6, 2025 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Nov 6, 2025 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Feb 26, 2025 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Dec 23, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 16, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 31, 2024 | WDRL | OTQR WITHDRAWAL FROM PUBLICATION | — |
| Apr 22, 2024 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Apr 16, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 1, 2023 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Nov 22, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 1, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 1, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 16, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 16, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 3, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 30, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 30, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 17, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 17, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 10, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 26, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 25, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 5, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 27, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 27, 2019 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 27, 2019 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 26, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 21, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 21, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 13, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 13, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 13, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 25, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 25, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 21, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 20, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 18, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 14, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 9, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |